Media Centre

Featured Media Release
 

19 May 2014 - 2013 Corporate Responsibility Report Published

GSK Australia and New Zealand today published the second annual corporate responsibility report, outlining key achievements in health, community and environmental sustainability during 2013.

 
 

Media Releases


International collaboration to develop inhaled form of oxytocin to manage bleeding after childbirth

GSK, Monash University, McCall MacBain Foundation, Grand Challenges Canada and Planet Wheeler Foundation join forces to develop oxytocin dry powder inhaler

26/09/2014

 

Night time bathroom visits - a trigger for men to visit the doctor

New Australian campaign launched that focusses on enlarged prostates

11/09/2014

 

Kimbra launches campaign to urge effective asthma management

Asthma Awareness Week – Popular recording artist and asthma sufferer Kimbra is joining forces with asthma experts and peak respiratory health groups today to launch the Asthma: Take Control campaign. The national campaign is urging people affected...

02/09/2014

 

Medicines Research Unit to Close

GSK today announced it will be closing the Medicines Research Unit at the Prince of Wales Hospital in Sydney.

28/08/2014

 

GSK Open Innovation brings opportunities to Australian & NZ innovators

An innovation program that helps develop ground-breaking health sector ideas around the world is calling upon Australian and New Zeland innovators to submit their ideas to the GSK Open Innovation website.

07/08/2014

 

GSK Response to Publication of Paracetamol in Low Back Pain Study (PACE)

Panadol is approved by the TGA for the effective relief of backache.

24/07/2014

 

New medicine for lupus now available in Australia

GSK is pleased to announce that BENLYSTA® (belimumab) is now available in Australia for use as an add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite...

23/07/2014

 

Incruse® Ellipta® (umeclidinium) approved in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline has announced today that the Therapeutic Goods Administration (TGA) has approved Incruse® Ellipta® (umeclidinium), a maintenance treatment to relieve symptoms in Australian adult patients with chronic obstructive pulmonary disease...

15/07/2014

 

Anoro® Ellipta® approved in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have proudly announced that the Therapeutic Goods Administration (TGA) has approved Anoro® Ellipta® (umeclidinium/vilanterol) as a maintenance bronchodilator treatment to relieve symptoms in...

09/07/2014

 

GSK RECOGNISES TOP POPPY GROWERS

Leaders in Australian poppy production, GSK awarded its top poppy producers at an award dinner

30/06/2014

1 2 3 4 5 6 7 8 9 10 11 >